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Background and Purpose Anesthesia regimen in patients undergoing mechanical thrombectomy 
(MT) is still an unresolved issue. 
Methods We compared the effect of anesthesia regimen using data from the German Stroke Reg-
istry-Endovascular Treatment (GSR-ET) between June 2015 and December 2019. Degree of disabili-
ty was rated by the modified Rankin Scale (mRS), and good outcome was defined as mRS 0–2. 
Successful reperfusion was assumed when the modified thrombolysis in cerebral infarction scale 
was 2b–3. 
Results Out of 6,635 patients, 67.1% (n=4,453) patients underwent general anesthesia (GA), 24.9% 
(n=1,650) conscious sedation (CS), and 3.3% (n=219) conversion from CS to GA. Rate of successful 
reperfusion was similar across all three groups (83.0% vs. 84.2% vs. 82.6%, P=0.149). Compared to 
the CA-group, the GA-group had a delay from admission to groin (71.0 minutes vs. 61.0 minutes, 
P<0.001), but a comparable interval from groin to flow restoration (41.0 minutes vs. 39.0 minutes). 
The CS-group had the lowest rate of periprocedural complications (15.0% vs. 21.0% vs. 28.3%, 
P<0.001). The CS-group was more likely to have a good outcome at follow-up (42.1% vs. 34.2% vs. 
33.5%, P<0.001) and a lower mortality rate (23.4% vs. 34.2% vs. 26.0%, P<0.001). In multivariable 
analysis, GA was associated with reduced achievement of good functional outcome (odds ratio 
[OR], 0.82; 95% confidence interval [CI], 0.71 to 0.94; P=0.004) and increased mortality (OR, 1.42; 
95% CI, 1.23 to 1.64; P<0.001). Subgroup analysis for anterior circulation strokes (n=5,808) showed 
comparable results. 
Conclusions We provide further evidence that CS during MT has advantages over GA in terms of 
complications, time intervals, and functional outcome. 
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Introduction
While mechanical thrombectomy (MT) is the standard of care 
in eligible patients with large vessel occlusion (LVO), the appro-
priate anesthesia regimen is still an unresolved issue. The pri-
mary goal of sedation management during MT is to enable the 
interventionalist to perform the procedure as quickly and safely 
as possible. However, studies on this topic have shown conflict-
ing results. A recent meta-analysis from three randomized sin-
gle-center trials showed an advantage for general anesthesia 
(GA) compared to conscious sedation (CS) in patients with an-
terior circulation strokes who underwent MT with respect to 
3-month outcome.1 Contrary to this, a post hoc analysis from 
797 patients from the Highly Effective Reperfusion Using Mul-
tiple Endovascular Devices (HERMES) Collaboration showed 
that patients treated without GA had a better 3-month out-
come compared to those treated under GA.2 Data from another 
registry on anesthesia regimens with 4,429 patients showed,3 
that GA was associated with worse functional outcome, espe-
cially when compared with local anesthesia. Due to the lack of 
evidence from large clinical trials on this topic, these results 
have to be interpreted with caution. The supposed advantages 
of GA would be the patients’ immobilization during MT, proper 
pain management, airway protection and therefore fewer peri-
procedural complications. The more optimal periprocedural 
conditions are said to lead to higher rates of successful reper-
fusion resulting in better functional outcome.1 On the other 
hand, GA may cause a delay before groin puncture and result in 
complications related to intensive care management leading to 
an overall delay in the hospital stay. Advantages of CS include 
clinical and neurological monitoring, fewer hemodynamic fluc-
tuations, and potentially shorter procedures. However, unpro-
tected airways and patient movement are believed to have a 
negative influence on functional outcome. Here we aimed to 
analyze the real-life practice of anesthesia regimen in MT-pa-
tients from the German Stroke Registry-Endovascular Treat-
ment (GSR-ET) and its impact on complications and outcome.4
Methods
Data from the GSR-ET (https://www.clinicaltrials.gov; 
NCT03356392) were analyzed. Details of the registry have been 
published previously.4,5 See Appendix 1 for steering committee 
members of GSR (GSR investigators). 
Study population 
Between June 2015 and December 2019, 6,635 patients from 
25 sites in Germany with acute ischemic stroke due to LVO, 
who were treated with MT, were included. The decision for MT 
was based on the interdisciplinary decision of treating physi-
cians including clinical and imaging parameters and according 
to national (German Neurological Society) and international 
guidelines (European Stroke Organization, American Heart As-
sociation).6-8
Stroke severity was assessed by the National Institutes of 
Health Stroke Scale (NIHSS). Pre- and post-stroke disability 
was rated by the modified Rankin Scale (mRS). Early infarct 
signs were assessed by the Alberta Stroke Program Early CT 
Score (ASPECTS). Site of occlusion was determined by comput-
ed tomography angiography, magnetic resonance angiography, 
or angiography. Reperfusion success was measured by the 
modified thrombolysis in cerebral infarction (mTICI) scale and 
mTICI 2b-3 was rated as successful reperfusion. 
The periprocedural anesthesia regimen was based on indi-
vidual and interdisciplinary decisions and in-house protocols. 
In general, patients received either GA or CS; a small group 
converted from CS to GA for various periprocedural reasons. In 
313 patients, the anesthesia regimen was not documented.
 
Statistical analysis 
Continuous variables were tested for normal distribution using 
the Kolmogorov-Smirnov test. Normally distributed data were 
presented as mean±standard deviation and non-normally dis-
tributed data as median (interquartile range) or counts and per-
centages. Clinical characteristics, imaging data, periprocedural 
times, and outcome parameters were compared across the three 
groups using the Kruskal-Wallis test or median-test, as appro-
priate. Binary logistic regression analysis was performed for 
good outcome (mRS 0–2) and mortality at follow-up, including 
variables that were either statistically or clinically (or biologi-
cally) significant. For logistic regression analysis, categorical 
variables were defined as follows: sex male=0, female=1; intra-
venous thrombolysis treatment no=0, yes=1; successful recana-
lization no=0, yes=1; type of anesthesia CS=0, GA=1; intracere-
bral hemorrhage (ICH) no=0, yes=1; tandem lesion no=0, yes=1; 
posterior circulation stroke no=0, yes =1; pretreatment with 
oral anticoagulants no=0, yes=1. Converted patients and pa-
tients with unknown anesthesia regimen were excluded from 
the logistic analysis. For all statistical testing, we used the SPSS 
version 25.0 for Windows (IBM Co., Armonk, NY, USA). 
Ethics
The study was conducted in accordance with the Declaration 
of Helsinki and was centrally approved by the Institutional Re-
view Board (IRB) of the Ludwig-Maximilians-Universität Mu-
nich (protocol No. 689-15). Further approval was obtained 
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Age (yr) 73.4±13.0 73.1±13.1 70.3±13.3 0.340
Female sex 835 (50.6) 2,265 (50.9) 98 (44.7) 0.206








pmRS ≤ 1 1,278 (77.5) 3,237 (72.7) 167 (76.3) 0.017
Baseline NIHSS 13 (8–11) 15 (10–19) 15 (9–18) <0.001
Drip and ship 800 (48.5) 1,834 (41.2) 108 (49.3) <0.001
BP systolic at admission 154.7±27.4 151.0±27.4 155.5±28.0 <0.001
BP diastolic at admission 84.4±17.0 82.0±17.0 86.0±16.0 <0.001
Heart rate at admission 82.4±19.1 81.5±19.2 84.5±18.5 0.015
OAC at admission 332 (20.1) 896 (20.1) 35 (16.0) 0.116
Risk factors
Arterial hypertension 1,229 (74.5) 3,265 (73.3) 157 (71.7) <0.001
Diabetes mellitus 342 (20.7) 934 (21.0) 46 (21.0) 0.119
Hypercholesterolemia 532 (32.2) 1,753 (39.4) 77 (35.2) <0.001
Current smoking 208 (12.6) 585 (13.1) 40 (18.3) <0.001
Atrial fibrillation 662 (40.1) 1,765 (39.6) 82 (37.4) 0.348
Imaging data
ASPECTS 9 (7–10) 9 (7–10) 8 (7–10) 0.010
Tandem lesion 221 (13.4) 730 (16.4) 39 (17.8) 0.011
Anterior circulation 1,572 (95.3) 3,786 (85.0) 194 (88.6) <0.001
Right-sided occlusion 810 (48.7) 1,824 (40.9) 90 (41.1) 0.002
Type of occlusion*
Basilar artery 50 (3.0) 556 (12.5) 17 (7.8) <0.001
Vertebral artery 6 (0.4) 121 (2.7) 3 (1.4) <0.001
PCA 30 (1.8) 147 (3.3) 8 (3.7) 0.003
ACA 35 (2.1) 108 (2.4) 3 (1.4) 0.521
Carotid-T 250 (15.2) 766 (17.2) 39 (17.8) 0.184
ICA intracranial 85 (5.2) 227 (5.1) 17 (7.8) 0.213
ICA extracranial 132 (8.0) 295 (6.6) 16 (7.3) 0.144
MCA, proximal M1 529 (32.1) 1,346 (30.2) 72 (32.9) 0.219
MCA, distal M1 394 (23.9) 778 (17.5) 40 (18.3) <0.001
MCA, M2 361 (21.9) 959 (21.5) 45 (20.5) 0.422
Time intervals (min)
Admission to groin 61.0 (40.0–89.0) 71.0 (47.0–103.0) 61.0 (41.0–83.0) <0.001
Groin to flow restoration 39.0 (25.0–63.0) 41.0 (26.0–65.0) 64.5 (42.0–100.0) <0.001
Admission to flow restoration 107.0 (76.0–143.0) 118.5 (88.0–160.0) 129.0 (97.8–179.0) <0.001
Treatment
IVT treatment 846 (51.3) 2,208 (49.6) 129 (58.9) 0.018
Additive medication during 
  thrombectomy
327 (19.8) 1,548 (34.8) 54 (24.7) <0.001
ASA 18 (1.1) 92 (2.1) 5 (2.3) 0.036
Clopidogrel 2 (0.1) 14 (0.3) 1 (0.5) 0.373
Ticagrelor 0 (0) 21 (0.5) 1 (0.5) 0.020
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from local IRBs according to local regulations. Informed con-
sent was not mandatory in accordance with the IRB approval 
since there were no study-specific procedures performed and 
data analysis of all patients undergoing MT was demanded by 
the governmental quality surveillance system. 
Results
Out of 6,635 patients from the GSR-ET, 67.1% (n=4,453) un-
derwent GA and 24.9% (n=1,650) CS during MT. In 3.3% of all 









Tirofiban 21 (1.3) 136 (3.1) 9 (4.1) <0.001
Abciximab 0 (0) 3 (0.1) 1 (0.5) 0.040
Heparin 226 (13.7) 1,067 (24.0) 33 (1.4) <0.001
rtPA 47 (2.8) 93 (2.1) 6 (2.7) 0.194
Acute treatment ipsilateral ICA 
(stenting and/or PTA)
169 (10.2) 526 (11.8) 25 (11.4) 0.110
No. of passages 2.0±1.6 2.2±1.8 2.5±1.9 <0.001
Periprocedural complications 248 (15.0) 934 (21.0) 62 (28.3) <0.001
Device malfunction 9 (0.5) 21 (0.5) 2 (0.9) 0.995
Dissection, perforation 42 (2.5) 130 (2.9) 14 (6.4) 0.007
Clot migration, embolization 55 (3.3) 185 (4.2) 9 (4.1) 0.426
ICH 29 (1.7) 127 (2.8) 13 (5.9) <0.001
Vasospasm 57 (3.5) 389 (8.7) 22 (10.0) <0.001
Resuscitation 8 (0.5) 13 (0.3) 2 (0.9) 0.070
Other 110 (6.7) 272 (6.1) 23 (10.5) 0.003









NIHSS 8 (3–16) 11 (4–20) 13 (5–23) <0.001
Complications 705 (42.7) 2,076 (46.6) 117 (53.5) 0.002
Malignant MCA infarction 69 (4.2) 284 (6.4) 15 (6.8) 0.001
Recurrent stroke 62(3.8) 264 (5.9) 6 (2.7) <0.001
ICH 187 (11.3) 625 (14.0) 47 (21.5) <0.001
Myocardial infarction 30 (1.8) 75 (1.7) 2 (0.9) 0.612
Groin hematoma 34 (2.1) 64 (1.4) 7 (3.2) 0.406
Groin aneurysm 14 (0.8) 30 (0.7) 1 (0.5) 0.693
Other complications 426 (25.8) 1,278 (28.7) 72 (32.9) 0.023
Hospital stay (day) 9.5±7.5 11.3±9.5 11.1±8.1 <0.001
Discharge








Mortality (mRS 6) 188 (11.4) 775 (17.4) 27 (12.3) <0.001
Values are presented as mean±standard deviation, number (%), or median (interquartile range). 
GSR, German Stroke Registry; pmRS, pre-stroke modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; BP, blood pressure; OAC, oral anti-
coagulation; ASPECTS, Alberta Stroke Program Early CT Score; PCA, posterior cerebral artery; ACA, anterior cerebral artery; ICA, internal carotid artery; MCA, 
middle cerebral artery; IVT, intravenous thrombolysis; ASA, acetylsalicylic acid; rtPA, recombinant tissue plasminogen activator; PTA, percutaneous translumi-
nal angioplasty; ICH, intracerebral hemorrhage; mTICI, modified thrombolysis in cerebral infarction; mRS, modified Rankin Scale.
*Multiple occlusion sites possible.
Table 1. Continued
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initial CS to GA, while the anesthesia regimen was not docu-
mented in 313 patients (4.7%). The CS- and GA-groups were 
of similar age and sex, but patients from the GA-group had 
higher pre-stroke modified Rankin Scale (pmRS) and higher 
NIHSS on admission (Table 1). CS-patients were more often 
admitted via drip and ship (48.5% vs. 41.2% vs. 49.3%, 
P<0.001). Further, the CS-group had more often patients with 
right-sided (48.7% vs. 40.9% vs. 41.1%, P=0.002) and anterior 
circulation stroke (95.3% vs. 85.0% vs. 88.6%, P<0.001). The 
rate of successful reperfusion was similar in all three groups 
(83.0% vs. 84.2% vs. 82.6%, P=0.149). While tandem lesions 
were more frequent in the GA-group (13.4% vs. 16.4% vs. 
17.8%, P=0.011), rate of acute treatment of ipsilateral internal 
carotid artery (stenting and/or percutaneous transluminal an-
gioplasty) was comparable in all groups (10.2% vs. 11.8% vs. 
11.4%, P=0.110). GA compared to CS was associated with a 
significant delay from admission to groin (61.0 minutes vs. 71.0 
minutes vs. 61.0 minutes, P<0.001). Time from groin to flow 
restoration did not differ between the GA- and the CS-groups 
(39.0 minutes vs. 41.0 minutes), while the converted group had 
a significantly longer time interval from groin to flow restora-
tion (64.5 minutes, P<0.001). Overall, the CS-group showed the 
lowest rate of periprocedural complications (15.0% vs. 21.0% 
vs. 28.3%, P<0.001). 
GA was independently associated with higher periprocedural 
complications (odds ratio [OR], 1.58; 95% confidence interval 
[CI], 1.35 to 1.86; P<0.001) (Table 2). In the GA-group, patients 
were more likely to receive intensive antithrombotic medica-
tions (Table 1). In the CS-group, rates of periprocedural ICH 
(1.7% vs. 2.8% vs. 5.9%, P<0.001) and complications during 
the whole hospital stay (42.7% vs. 46.6% vs. 53.5%, P=0.002) 
were lowest. Hospital stay was significantly shorter in the CS-
group compared to GA-group and the converted group 
(9.5±7.5 days vs. 11.3±9.5 days vs. 11.1±8.1 days, P<0.001). 
At 24 hours, CS patients performed better with respect to 
NIHSS (8 vs. 11 vs. 13, P<0.001). Three-month follow up was 
not available in 15.4% (n=1,021). The patients in the CS-group 
were more likely to achieve good outcome (42.1% vs. 34.2% 
vs. 33.5%, P<0.001) and had a lower rate of mortality (23.4% 
vs. 32.4% vs. 26.0%, P<0.001) (Figure 1A). 
In multivariable analysis, GA was associated with reduced 
achievement of good functional outcome (OR, 0.82; 95% CI, 
0.71 to 0.94; P=0.004) and increased mortality (OR, 1.42; 95% 
CI, 1.23 to 1.64; P<0.001) (Tables 3 and 4). 
We performed an additional analysis, restricted to patients 
with anterior circulation strokes (n=5,808) (Supplementary Ta-
ble 1), which showed comparable results with respect to time 
delay, complications, and outcome parameters (Figure 1B and 
Supplementary Tables 2 and 3). 
Discussion
Here we present by far the largest sample size on anesthesia 
regimens in 6,635 MT-patients with the following results: GA 
was the most common strategy in centers within the GSR-ET; 
more than two-thirds of the patients received MT under GA. 
The GA-rate is considerably higher than reported in data from 
clinical trials or registry data with about 30% of patients re-
ceiving GA (28.0% to 37.6%).9-12 In about 12% of patients 
starting MT under CS, a conversion to GA was necessary (cor-
Table 2. Logistic regression for periprocedural complications during mechanical thrombectomy in general anesthesia- and conscious sedation-groups 
Variable OR 95% CI P
Age 0.99 0.98–0.99 0.002
Sex 1.09 0.93–1.27 0.291
pmRS 1.11 1.03–1.18 0.004
NIHSS at admission 0.99 0.98–1.01 0.533
Treatment with IVT 1.02 0.86–1.21 0.840
General anesthesia 1.58 1.35–1.86 <0.001
Tandem lesion 1.21 0.98–1.50 0.080
Posterior circulation stroke 0.57 0.13–2.59 0.470
Time from admission to groin puncture 1.00 0.99–1.00 0.153
ASPECTS 1.01 0.96–1.05 0.787
No. of passages 1.18 1.14–1.23 <0.001
Pretreatment (OAC) 0.78 0.62–0.97 0.025
OR, odds ratio; CI, confidence interval; pmRS, pre-stroke modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IVT, intravenous thromboly-
sis; ASPECTS, Alberta Stroke Program Early CT Score; OAC, oral anticoagulation. 
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6,635  mRS score at 3-month follow-up
1,650  Conscious sedation
(24.9%)




P<0.001 for median mRS, good outcome and mortality




18% 14% 11% 12% 13% 23%9%
9% 14% 12% 12% 12% 33%8%
12% 11% 12% 14% 11% 26%16%
▒0  ▒1  ▒2  ▒3  ▒4  ▒5  ▒6
5,808  mRS score at 3-month follow-up anterior circulation
1,572  Conscious sedation
(27.1%)




P<0.001 for median mRS, good outcome and mortality




▒0  ▒1  ▒2  ▒3  ▒4  ▒5  ▒6
17% 14% 11% 12% 13% 24%9%
9% 14% 12% 12% 13% 33%8%
13% 11% 11% 12% 12% 25%16%
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responding to 3% of the whole cohort). This is in line with 
rates that ranged from about 10% to 15% in other studies.13-17 
In our study, patients from the CS-group performed better with 
respect to clinical outcomes at 24 hours, at discharge, and at 
follow-up after 3 months than patients with MT under GA. 
Time intervals showed delayed start of groin puncture in GA-
patients and therefore longer time intervals from admission to 
flow restoration. Successful reperfusion rate was similar across 
all three patient groups. More periprocedural and in-hospital 
complications were observed under GA—independently of pos-
sible confounders, such as tandem lesions, posterior circulation 
stroke, or number of passages. The interpretation of this result 
remains speculative. Possibly, there are confounders we cannot 
address appropriately yet, such as changes in blood pressure 
caused by GA or imbalances in baseline parameters. Thus the 
regression analysis cannot appropriately adjust for all these 
confounders. Well-balanced groups in clinical trials would be 
necessary to overcome these shortcomings.
Overall, these findings are in contrast to prior studies, but in 
line with data from another registry analyzing 4,429 patients.3 
A recent meta-analysis from three clinical trials showed an ad-
vantage of GA with respect to outcome, an effect that was 
most probably driven by higher rates of successful reperfusion 
in the GA-group.1 Investigators speculated that GA leads to 
more optimal interventional conditions, resulting in higher re-
perfusion rates.1 A post hoc analysis from 797 patients from 
the HERMES collaboration showed non-GA patients to have a 
higher rate of good outcome at 3 months compared to GA-pa-
tients.2 However, in this post hoc analysis only 30% of patients 
were treated under GA. Besides, they used data from RCTs, 
which were much more homogenous with respect to pmRS, 
baseline parameters, and occlusion side than in our study.2 
Poorer outcome in the GA-group was most probably not only 
caused by periprocedural complications but could partly be ex-
plained by the fact that the GA- and CS-groups were not fully 
balanced. With respect to periprocedural complications, we 
observed higher rates of dissection and perforation, ICH, and 
vasospasm in the GA-group and the converted group. These 
Table 3. Logistic regression for good outcome in general anesthesia- and conscious sedation-groups at follow-up
Variable OR 95% CI P
Age 0.95 0.95–0.96 <0.001
Sex 1.01 0.87–1.17 0.885
pmRS 0.53 0.49–0.58 <0.001
NIHSS at admission 0.89 0.88–0.90 <0.001
Treatment with IVT 1.73 1.50–2.00 <0.001
Successful reperfusion (mTICI 2b/3) 4.87 3.82–6.22 <0.001
General anesthesia 0.82 0.71–0.94 0.004
ICH 0.26 0.21–0.33 <0.001
Time from admission to groin 0.99 0.999–1.00 0.019
OR, odds ratio; CI, confidence interval; pmRS, pre-stroke modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IVT, intravenous thromboly-
sis; mTICI, modified thrombolysis in cerebral infarction; ICH, intracerebral hemorrhage.
Table 4. Logistic regression for mortality in general anesthesia- and conscious sedation-groups at follow-up
Variable OR 95% CI P
Age 1.06 1.05–1.07 <0.001
Sex 0.90 0.78–1.05 0.167
pmRS 1.35 1.27–1.42 <0.001
NIHSS at admission 1.09 1.07–1.10 <0.001
Treatment with IVT 0.64 0.56–0.74 <0.001
Successful reperfusion (mTICI 2b/3) 0.28 0.24–0.34 <0.001
General anesthesia 1.42 1.23–1.64 <0.001
ICH 2.71 2.26–3.25 <0.001
Time from admission to groin 1.00 1.00–1.00 0.114
OR, odds ratio; CI, confidence interval; pmRS, pre-stroke modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IVT, intravenous thromboly-
sis; mTICI, modified thrombolysis in cerebral infarction; ICH, intracerebral hemorrhage.
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complications could have been clinical reason for conversion 
from CS to GA. 
A recent analysis from a prospective Italian registry (Italian 
Registry of Endovascular Treatment of Acute Stroke [IRETAS]) 
showed that two-thirds of these patients were treated with CS 
or local anesthesia. In contrast, in centers from the GSR-ET two 
thirds of patients underwent MT under GA. Our patients had a 
pmRS of 0–1 in about 80% compared to up to 90% in IRETAS. 
ASPECTS in the GSR was 8–9 and 10 in IRETAS. This might par-
tially explain the observation of different sedation regimens. 
However, due to different sedation regimens and different study 
populations the comparability of both studies is limited. Besides, 
our data provide further evidence for anesthesia and sedation 
management, especially regarding periprocedural complications 
that have been less well explored using a large dataset. 
Our data show significantly lower systolic and diastolic blood 
pressure and heart rate at admission in the GA-group. Howev-
er, we have no data on the temporal changes of blood pressure 
data, especially a significant drop which potentially increases 
infarct size, leading to poor outcome.18 In the GA-group, the 
cumulative dose of norepinephrine—reflecting the drop in 
blood pressure under GA—was an independent predictor of an 
unfavorable outcome.19 On the other hand, vasospasm occurred 
most frequently under GA. As high PaO2 is discussed to cause 
intracerebral vasospasm, this effect might be more likely to oc-
cur under GA than under CS.20 However, our data do not allow 
any conclusion on causality to be drawn. Thus, the causality 
between GA and higher occurrence of vasospasm as a peripro-
cedural complication is speculative. In converted patients, we 
neither provided information on the time of the periprocedural 
complication nor of the conversion from GA to CS. Therefore, 
we cannot conclude that the periprocedural complication rate 
is lower in the GA-group. 
With regard to the total complication rate during the hospi-
tal stay, there were clear differences with a disadvantage of 
GA, especially regarding the occurrence of ICH and all other 
complications. In the GA-group, antithrombotic medication 
was used more intensively. In terms of complications, rates of 
ICH were highest in patients treated under GA. In summary, 
patients under GA performed worse in every aspect. 
We observed no influence of anesthesia regimen on success-
ful reperfusion rates. The number of passages was highest in 
the converted group and lowest in the CS-group. However, in 
the GA-group, periprocedural time to groin puncture was ex-
tended by an average of 10 minutes and the delay was not 
compensated by the MT procedure time. Retrospective studies 
have suggested that the time delay through intubation may 
lead to worse outcome.21 While patients undergoing MT under 
CS had slightly lower NIHSS at admission (13 vs. 15 in median), 
the difference in clinical stroke severity continued and even in-
creased with respect to NIHSS and mRS after 24 hours, at dis-
charge, and at 3-month follow-up. Regression analysis showed 
that CS was independently associated with higher probability 
of good outcome and lower odds for mortality at 3 months ad-
justed to confounders like baseline NIHSS. Patients who con-
verted from CS to GA also had better outcome than patients in 
the GA- group. Besides poorer clinical outcome, GA was asso-
ciated with a longer hospital stay of 2 days.
The strengths of our study include the large study cohort 
prospectively collected from a nationwide multicenter registry. 
Our data therefore represent clinical decisions on sedation 
management and anesthesia regimen in daily life practice, 
outside clinical trials. We observed the same results for the 
whole cohort of LVO patients as well as for anterior circula-
tion strokes. We were able to analyze detailed information on 
complications and clinical follow-up. Given that it is unlikely 
that evidence will be established from large clinical trials in 
the near future, our results provide further evidence based on 
observational data that patients benefit from CS compared to 
GA. 
However, our study has some limitations. Our data are ob-
servational, non-randomized and non-controlled. Therefore, 
interpretation of the data is prone to bias. Underlying selec-
tion bias for decision for an anesthesia regimen have to be 
discussed as well, even if individual variables in the patient 
baseline data did not differ. Individual clinical parameters, 
such as pmRS, NIHSS at admission or presence of tandem le-
sions, could have contributed to the decision for anesthesia 
regimens; however, we cannot analyze this in more detail 
retrospectively. Furthermore, we provide no information 
about the periprocedural use of sedative agents (type, dos-
age), further need of intensive care treatment, the duration 
of mechanical ventilation, and the reason for conversion from 
GA to CS. Apart from the vital signs at admission, there are 
no extensive data on the course of these vital signs and their 
impact on complications and outcome. Further, the CS-group 
also included patients who only received local anesthesia as 
a distinction between local anesthesia and CS was not made 
in the GSR-ET register. 
Conclusions
Our study showed an influence on the functional and clinical 
outcome after MT by the choice of anesthesia regimen with 
advantages for CS compared to GA in terms of complications, 
functional outcome, and mortality. 
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Appendix 1. GSR investigators
Name Degree Organization Role Contribution
Tobias Boeckh-Behrens MD Klinikum r.d.Isar, Munich, Germany Site Investigator German Stroke Registry - Steering Committee
Silke Wunderlich MD Klinikum r.d.Isar, Munich, Germany Site Investigator German Stroke Registry - Steering Committee
Arno Reich MD Uniklinik RWTH Aachen, Germany Site Investigator German Stroke Registry - Steering Committee
Anastasios Mpotsaris MD Uniklinik RWTH Aachen, Germany Site Investigator German Stroke Registry - Steering Committee
Martin Wiesmann MD Uniklinik RWTH Aachen, Germany Site Investigator German Stroke Registry - Steering Committee
Ulrike Ernemann MD Tübingen University Hospital, Germany Site Investigator German Stroke Registry - Steering Committee
Till-Karsten Hauser MD Tübingen University Hospital, Germany Site Investigator German Stroke Registry - Steering Committee
Christian H Nolte MD Charite Campus Benjamin Franklin Site Investigator German Stroke Registry - Steering Committee
Eberhard Siebert MD Charité – Campus Benjamin Franklin und Campus 
  Charité Mitte, Berlin, Germany
Site Investigator German Stroke Registry - Steering Committee
Sarah Zweynert MD Charité - Campus Virchow Klinikum, Berlin, Germany Site Investigator German Stroke Registry - Steering Committee
Georg Bohner MD Charité - Campus Virchow Klinikum, Berlin, Germany Site Investigator German Stroke Registry - Steering Committee
Alexander Ludolph MD Sana Klinikum Offenbach, Germany Site Investigator German Stroke Registry - Steering Committee
Karl-Heinz Henn MD Sana Klinikum Offenbach, Germany Site Investigator German Stroke Registry - Steering Committee
Waltraud Pfeilschifter MD Uniklinik Frankfurt/ Main, Germany Site Investigator German Stroke Registry - Steering Committee
Marlis Wagner MD Uniklinik Frankfurt/ Main, Germany Site Investigator German Stroke Registry - Steering Committee
Joachim Röther MD Asklepios Klinik Altona, Hamburg, Germany Site Investigator German Stroke Registry - Steering Committee
Bernd Eckert MD Asklepios Klinik Altona, Hamburg, Germany Site Investigator German Stroke Registry - Steering Committee
Jörg Berrouschot MD Klinikum Altenburger Land, Altenburg, Germany Site Investigator German Stroke Registry - Steering Committee
Albrecht Bormann MD Klinikum Altenburger Land, Altenburg, Germany Site Investigator German Stroke Registry - Steering Committee
Anna Alegiani MD University Medical Center Hamburg-Eppendorf, 
  Hamburg, Germany
Site Investigator German Stroke Registry - Steering Committee
Jens Fiehler MD University Medical Center Hamburg-Eppendorf, 
  Hamburg, Germany
Site Investigator German Stroke Registry - Steering Committee
Fabian Flottmann MD University Medical Center Hamburg-Eppendorf, 
  Hamburg, Germany
Site Investigator German Stroke Registry - Steering Committee
Christian Gerloff MD University Medical Center Hamburg-Eppendorf, 
  Hamburg, Germany
Site Investigator German Stroke Registry - Steering Committee
Götz Thomalla MD University Medical Center Hamburg-Eppendorf, 
  Hamburg, Germany
Site Investigator German Stroke Registry - Steering Committee
Elke Hattingen MD University Hospital Bonn, Germany Site Investigator German Stroke Registry - Steering Committee
Gabor Petzold MD University Hospital Bonn, Germany Site Investigator German Stroke Registry - Steering Committee
Sven Thonke MD Klinikum Hanau, Germany Site Investigator German Stroke Registry - Steering Committee
Christopher Bangard  MD Klinikum Hanau, Germany Site Investigator German Stroke Registry - Steering Committee
Christoffer Kraemer MD Klinikum Lüneburg, Germany Site Investigator German Stroke Registry - Steering Committee
Martin Dichgans MD Ludwig Maximilian University of Munich, Germany Site Investigator German Stroke Registry - Steering Committee
Marios Psychogios MD Georg-August-Universität Göttingen, Germany Site Investigator German Stroke Registry - Steering Committee
Jan Liman MD Georg-August-Universität Göttingen, Germany Site Investigator German Stroke Registry - Steering Committee
Martina Petersen MD Klinikum Osnabrück, Germany Site Investigator German Stroke Registry - Steering Committee
Florian Stögbauer MD Klinikum Osnabrück, Germany Site Investigator German Stroke Registry - Steering Committee
Peter Kraft MD University Hospital Würzburg, Germany Site Investigator German Stroke Registry - Steering Committee
Mirko Pham MD University Hospital Würzburg, Germany Site Investigator German Stroke Registry - Steering Committee
Michael Braun MD Bezirkskrankenhaus Günzburg, Germany Site Investigator German Stroke Registry - Steering Committee
Gerhard F. Hamann MD Bezirkskrankenhaus Günzburg, Germany Site Investigator German Stroke Registry - Steering Committee
Andreas Kastrup MD Klinikum Bremen Mitte, Germany Site Investigator German Stroke Registry - Steering Committee
Christian Roth  MD Klinikum Bremen Mitte, Germany Site Investigator German Stroke Registry - Steering Committee
Klaus Gröschel MD University Medical Center Mainz, Germany Site Investigator German Stroke Registry - Steering Committee
Timo Uphaus MD University Medical Center Mainz, Germany Site Investigator German Stroke Registry - Steering Committee
Volker Limmroth MD Kliniken Köln, Germany Site Investigator German Stroke Registry - Steering Committee
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Age (yr) 73.4±13.0 73.4±13.0 72.0±12.8 0.168
Female sex 799 (50.8) 1,984 (52.4) 98 (50.5) 0.516








pmRS ≤1 1,222 (77.7) 2,737 (72.3) 150 (77.3) 0.002
Baseline NIHSS 14 (9–17) 15 (10–19) 15 (10–19) <0.001
Drip and ship 773 (49.2) 1,564 (41.3) 94 (48.5) <0.001
Admission BP systolic 154.4±27.5 151.1±–27.2 154.1±27.6 <0.001
Admission BP diastolic 84.1±16.9 82.2±16.8 85.6±15.9 <0.001
Admission heartrate 81.9±18.2 81.9±19.4 84.3±18.7 0.111
OAC at admission 315 (20.0) 787 (20.8) 32 (16.5) 0.067
Risk factors
Arterial hypertension 1,165 (74.1) 2,774 (73.3) 139 (71.6) 0.004
Diabetes mellitus 326 (20.7) 792 (20.9) 42 (21.6) 0.459
Hypercholesterolemia 512 (32.6) 1,509 (39.9) 69 (35.6) <0.001
Current smoking 197 (12.5) 513 (13.5) 35 (18.0) <0.001
Atrial fibrillation 637 (40.5) 1,550 (40.9) 74 (38.1) 0.082
Imaging data
ASPECTS 9 (7–10) 9 (7–10) 8 (7–10) 0.010
Tandem lesion 216 (13.7) 598 (15.8) 37 (19.1) 0.020
Right-sided occlusion 791 (50.3) 1,728 (45.7) 85 (43.8) 0.001
Time intervals (min)
Admission to groin 60.0 (39.0–88.0) 70.0 (47.0–100.0) 60.0 (41.0–81.0) <0.001
Groin to flow restoration 39.0 (25.0–63.0) 41.0 (26.0–65.0) 64.0 (42.0–100.0) <0.001
Admission to flow restoration 106.0 (75.0–142.0) 118.0 (88.0–159.0) 129.0 (97.0–179.0) <0.001
Treatment
IVT treatment 809 (51.5) 1,910 (50.4) 121 (62.4) 0.005
Additive medication during 
thrombectomy
313 (19.9) 1,305 (34.5) 44 (22.7) <0.001
ASA 16 (1.0) 84 (2.2) 5 (2.6) 0.010
Clopidogrel 2 (0.1) 11 (0.3) 1 (0.5) 0.420
Ticagrelor 0 (0) 16 (0.4) 1 (0.5) 0.034
Tirofiban 18 (1.1) 84 (2.2) 8 (4.1) 0.003
Abciximab 12 (0.8) 0 (0) 0 (0) 1.000
Heparin 218 (13.9) 912 (24.1) 24 (12.4) <0.001
rtPA 43 (2.7) 78 (2.1) 6 (3.1) 0.239
Acute treatment ipsilateral ICA 
(stenting and/or PTA)
167 (10.6) 526 (13.9) 25 (12.9) 0.015
No. of passages 2.0±1.6 2.2±1.9 2.5±1.9 <0.001
Periprocedural complications 230 (14.6) 802 (21.2) 57 (29.4) <0.001
Device malfunction 8 (0.5) 18 (0.5) 2 (1.0) 0.557
Dissection, perforation 41 (2.6) 105 (2.8) 11 (5.7) 0.049
Clot migration, embolization 54 (3.4) 154 (4.1) 9 (4.6) 0.480
ICH 29 (1.8) 111 (2.9) 12 (6.2) <0.001










Vasospasm 56 (3.6) 344 (9.1) 20 (10.3) <0.001
Other 108 (6.9) 220 (5.8) 22 (11.3) 0.005









NIHSS 8 (4–16) 11 (5–19) 14 (5–22) <0.001
Complications 682 (43.4) 1,765 (46.6) 103 (53.1) 0.012
Malignant middle cerebral artery 
  infarction
67 (4.3) 278 (7.3) 15 (7.7) <0.001
Recurrent stroke 56 (3.6) 203 (5.4) 4 (2.1) 0.004
ICH 184 (11.7) 669 (15.0) 44 (22.7) <0.001
Groin haematoma 34 (2.2) 55 (1.5) 7 (3.6) 0.384
Groin aneurysma 14 (0.9 26 (0.7) 1 (0.5) 0.381
Other complications 412 (26.2) 1,055 (27.9) 61 (31.4) 0.104









NIHSS 4 (1–11) 5 (2–12) 6 (2–13) 0.024
Mortality (mRS 6) 180 (11.5) 625 (16.5) 22 (12.0) <0.001
Values are presented as mean±standard deviation, number (%), or median (interquartile range). 
GSR, German Stroke Registry; pmRS, pre-stroke modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; BP, blood pressure; OAC, oral anti-
coagulation; ASPECTS, Alberta Stroke Program Early CT Score; IVT, intravenous thrombolysis; ASA, acetylsalicylic acid; rtPA, recombinant tissue plasminogen 
activator; ICA, internal carotid artery; PTA, percutaneous transluminal angioplasty; ICH, intracerebral hemorrhage; mTICI, modified thrombolysis in cerebral in-
farction; mRS, modified Rankin Scale.
Supplementary Table 1. Continued
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Supplementary Table 3. Logistic regression for mortality in anterior circulation stroke patients at follow-up
Variable OR 95% CI P
Age 1.07 1.06–1.07 <0.001
Sex 0.88 0.75–1.04 0.126
pmRS 1.37 1.29–1.46 <0.001
NIHSS at admission 1.10 1.09–1.12 <0.001
Treatment with IVT 0.67 0.57–0.79 <0.001
Successful reperfusion (mTICI 2b/3) 0.28 0.23–0.34 <0.001
General anesthesia 1.38 1.19–1.61 <0.001
ICH 2.73 2.26–3.31 <0.001
Time admission to groin 1.00 1.00–1.00 0.323
OR, odds ratio; CI, confidence interval; pmRS, pre-stroke modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IVT, intravenous thromboly-
sis; mTICI, modified thrombolysis in cerebral infarction; ICH, intracerebral hemorrhage.
Supplementary Table 2. Logistic regression for good outcome in anterior circulation stroke patients at follow-up 
Variable OR 95% CI P
Age 0.95 0.95–0.96 <0.001
Sex 0.99 0.84–1.15 0.859
pmRS 0.51 0.47–0.56 <0.001
NIHSS at admission 0.88 0.86–0.89 <0.001
Treatment with IVT 1.57 1.35–1.84 <0.001
Successful reperfusion (mTICI 2b/3) 5.41 4.15–7.05 <0.001
General anesthesia 0.86 0.74–0.99 0.041
ICH 0.25 0.20–0.31 <0.001
Time groin to flow restoration 0.99 0.99–1.00 0.009
OR, odds ratio; CI, confidence interval; pmRS, pre-stroke modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; IVT, intravenous thromboly-
sis; mTICI, modified thrombolysis in cerebral infarction; ICH, intracerebral hemorrhage.
